Good evening :)
$
₹
Pulmonx Corp

Pulmonx Corp

LUNG

NASDAQ
Asset Logo

Pulmonx Corp

LUNG

NASDAQ
$2.632.92% (+0.07)
$
₹
$2.632.92% (+0.07)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Medical Devices

Micro Cap

With a market cap of $119.5M the stock is ranked 4575

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

3.41
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-1.01
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-47.93%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 5 analysts reports

Buy
3 analysts
Hold
2 analysts
Sell
0 analyst

Price Upside

+44.53%

Earnings Growth

+26.5%

Rev. Growth

+0.59%

See Detailed Forecast

Company Profile

Company Profile

Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Abbott Laboratories
ABT
Abbott Laboratories
P/E Ratio
42.94
42.94
1Y Return
7.25%
7.25%
Buy Reco %
82.14
82.14
Intuitive Surgical Inc
ISRG
Intuitive Surgical Inc
P/E Ratio
58.29
58.29
1Y Return
12.11%
12.11%
Buy Reco %
76.47
76.47
Danaher Corporation
DHR
Danaher Corporation
P/E Ratio
38.89
38.89
1Y Return
10.7%
10.7%
Buy Reco %
83.33
83.33
Medtronic PLC
MDT
Medtronic PLC
P/E Ratio
25.78
25.78
1Y Return
15.97%
15.97%
Buy Reco %
66.66
66.66
Stryker Corporation
SYK
Stryker Corporation
P/E Ratio
36.17
36.17
1Y Return
6.31%
6.31%
Buy Reco %
76.66
76.66
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 44.53% growth, versus a trailing 3-year CAGR of -35.66%.

2026
Current$2.56Baseline
Analyst Target - 1 year
Target$3.7+44.53%

All values in $

202220232024202520262027$5.00$8.01$11.02Target+44.53%
2026
Current$2.56Baseline
Analyst Target - 1 year
Target$3.7+44.53%

All values in $

Revenue Forecast

Revenue Forecast

Lower revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 0.59% growth, versus a trailing 3-year CAGR of 19.03%.

2025
Current$90.49Baseline
Forecast for Dec 2026
High$91.5+1.11%
Average$91.03+0.59%
Low$90.5+0%

All values in $ Million

20212022202320242025202648.4153.6668.6783.7890.49Low-0%Average+0.59%High+1.11%
2025
Current$90.49Baseline
Forecast for Dec 2026
High$91.5+1.11%
Average$91.03+0.59%
Low$90.5+0%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-1.33Baseline
Forecast for Dec 2026
High$-0.97+27.07%
Average$-0.98+26.5%
Low$-0.99+25.56%

All values in $

202120222023202420252026-1.31-1.59-1.6-1.4-1.33Low+25.56%Average+26.5%High+27.07%
2025
Current$-1.33Baseline
Forecast for Dec 2026
High$-0.97+27.07%
Average$-0.98+26.5%
Low$-0.99+25.56%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

22.5
-10.4
20.5
-13.6
22.7
-10
22.8
-8.3
Q4 2025
Q1 2026
Q2 2026
Q3 2026
Revenue
Net Income
Financial YearQ2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Total Revenue20.7820.3823.7622.5323.8521.5022.5920.5822.7522.83
Net Income-15.32-14.14-13.17-14.44-15.17-13.95-10.42-13.65-10.08-8.39
Net Profit Margin-73.74%-69.37%-55.43%-64.10%-63.59%-64.91%-46.13%-66.32%-44.29%-36.75%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareMedical Devices

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Pulmonx Corp -3.41-
Abbott Laboratories42.943.701.56
Intuitive Surgical Inc58.299.742.04
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare LUNG with any stock or ETF
Compare LUNG with any stock or ETF
Comparing from
LUNG
ABT
ISRG
Loading...

Frequently asked questions

  1. Pulmonx Corp (LUNG) share price today is $2.63 as of November 6, 2026 at 10:18 PM IST. The stock touched a day high of $2.65 and a day low of $2.51.

  2. Pulmonx Corp stock trades on NASDAQ under the ticker symbol LUNG.

  3. Pulmonx Corp's market capitalization is $119.53M as of November 6, 2026 at 10:18 PM IST.

  4. Pulmonx Corp's price-to-earnings (P/E) ratio is N/A as of November 6, 2026.

  5. Pulmonx Corp's price-to-book (P/B) ratio is 3.41 as of November 6, 2026.

  6. Yes, You can buy Pulmonx Corp shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Pulmonx Corp shares in three steps: 1. Search Pulmonx Corp on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Pulmonx Corp trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Pulmonx Corp (LUNG) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 3.795 shares at the current price of $2.63.

Loading...